# Optimising TREATment for Severe Gram-Negative Bacterial Infections

> **NCT07004049** · PHASE4 · RECRUITING · sponsor: **National University of Singapore** · enrollment: 600 (estimated)

## Conditions studied

- Bloodstream Infection
- Ventilator Associated Bacterial Pneumonia
- Hospital Acquired Bacterial Pneumonia
- Carbapenem Resistant Bacterial Infection
- Multidrug Resistance

## Interventions

- **DRUG:** Colistin/Polymyxin B + Sulbactam
- **DRUG:** Colistin/Polymyxin B + Tigecycline/Eravacycline
- **DRUG:** Colistin/Polymyxin B + Meropenem
- **DRUG:** Ceftazidime-avibactam + Sulbactam
- **DRUG:** Ceftazidime-avibactam + Fosfomycin
- **DRUG:** Ceftazidime-avibactam
- **DRUG:** Ceftazidime-avibactam + Aztreonam
- **DRUG:** Ceftazidime-avibactam + Colistin/Polymyxin B
- **DRUG:** High-dose meropenem
- **DRUG:** Meropenem + Fosfomycin
- **DRUG:** Meropenem-vaborbactam
- **DRUG:** Cefiderocol
- **DRUG:** Ceftolozane-tazobactam
- **DRUG:** Ceftolozane-tazobactam + Meropenem

## Key facts

- **NCT ID:** NCT07004049
- **Lead sponsor:** National University of Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-21
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-06-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07004049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07004049, "Optimising TREATment for Severe Gram-Negative Bacterial Infections". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07004049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*